We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Oral Nadolol for the Treatment of Infantile Hemangiomas: A Single-Institution Retrospective Cohort Study.
- Authors
Randhawa, Harkamal Kaur; Sibbald, Cathryn; Garcia Romero, Maria Teresa; Pope, Elena
- Abstract
Background Beta-blockers have become the treatment of choice for problematic infantile hemangiomas ( IHs). Nadolol, a nonselective beta-blocker with potential dosing advantages and a better safety profile than that of other beta-blockers, has been studied as an alternative therapeutic option. Our objective was to characterize the efficacy and safety of oral nadolol in the treatment of proliferating IHs. Methods A retrospective cohort study was conducted at the Hospital for Sick Children between February 2010 and April 2012 in patients treated with nadolol for proliferating IHs causing functional impairment or cosmetic disfigurement. The primary outcome was the percentage involution measured independently by two assessors who scored changes in the extent of IHs by comparing serial photographs using a 100-mm visual analogue scale ( VAS), on which 5 mm represented 10% change. Results Forty-four patients treated with nadolol for IHs with adequate photographic documentation were identified. The median age at presentation was 4.5 months (interquartile range 1.5-7.9 mos). There was a mean improvement of 91.8 ± 11.1%. At least 50% improvement was noted in 42 (95%) patients and 75% improvement in 39 (89%) patients. The mean time to 50% and 75% improvement was 2.9 and 3.7 months, respectively. Analysis of variance showed that younger age at the time of treatment start was associated with a higher mean VAS score (% involution) (p < 0.05). Treatment duration (mean 9.5 ± 5.6 months) had no significant effect on VAS score. Test of interobserver correlation showed good agreement (intraclass correlation coefficient = 0.86, p = 0.001). Conclusions Oral nadolol is efficacious in patients with problematic IHs. Further large-scale prospective comparative studies are warranted to compare nadolol with other beta-blockers.
- Subjects
NADOLOL; HEMANGIOMAS; ADRENERGIC beta blockers; ANALYSIS of variance; ADRENOCORTICAL hormones; THERAPEUTICS
- Publication
Pediatric Dermatology, 2015, Vol 32, Issue 5, p690
- ISSN
0736-8046
- Publication type
Article
- DOI
10.1111/pde.12655